Cynbiose is a preclinical CRO specialized in non-human primate (NHP) translational models for biomedical research since 2008. They maintain a France-based AAALAC-accredited animal facility for toxicological studies. Their brand new state-of-the-art facility can also accommodate studies requiring biosafety environments from ABSL-1 to 3, as well as GMOs such as viral vector-based gene therapies.

The NHP model is well suited to predict pharmacokinetic and pharmacodynamic parameters, guide the selection of a safe starting dose for FIH trials, and provide valuable data on the potential toxicity of the candidate.

Their non-GLP preclinical services include:

– Pharmacokinetics (PK, central pharmacokinetics) and pharmacodynamics (PD) profiles

– In vivo biodistribution studies: biodistribution pattern (tissues, fluids such as CSF), Kpuu determination, and non-invasive imaging technologies

– Preclinical safety assessment, DRF, MTD, immunotoxicity, immunogenicity studies

– Immunopharmacology models

– Dedicated solutions: Nose-to-brain delivery strategies, Inhaled products, Gene therapies

Their state-of-the-art France-based animal facility has been AAALAC accredited since 2015. Their proven platform can operate studies in biosafety levels up to level 3, as well as GMOs C1-2, in a GLP-like environment.

Cynbiose combines ten years of preclinical experience and a wide range of cutting-edge capabilities to serve biopharmaceutical companies. Driven by passion and curiosity for science, their sponsors value them as trusted, reliable, flexible, and innovative partners.

–  Therapeutic areas: Central nervous system (CNS), Oncology, Infectious diseases, Respiratory diseases, Immune disorders & inflammation

–  Based in: Marcy l’Etoile (FRANCE)

–  Employees: 11 -50

– Created in: 2008